Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisocabtagene maraleucel + ibrutinib
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Lisocabtagene maraleucel + ibrutinib is a combination therapy under investigation for the treatment of relapsed or refractory B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed chimeric antigen receptor (CAR) T cell therapy that genetically modifies a patient's own T cells to express a CAR targeting the CD19 antigen on B cells. This enables the immune system to recognize and destroy malignant B cells[1][4][5]. Ibrutinib is an oral small molecule Bruton’s tyrosine kinase inhibitor that blocks signaling pathways essential for cancer cell proliferation and survival[2][3]. The combination aims to enhance anti-tumor efficacy by leveraging both direct cytotoxicity from CAR-T cells and disruption of tumor-supportive signaling by ibrutinib. Clinical studies have shown promising response rates in heavily pretreated CLL/SLL patients, including those previously treated with BTK inhibitors like ibrutinib[6][8].
- Other names
- lisocabtagene maraleucel + ibrutinib
02
Targets
BTK (Bruton tyrosine kinase)CD19 (B lymphocyte antigen CD19)EGFR (Epidermal growth factor receptor)ITK (Interleukin 2-inducible T-cell kinase)
Beyond the preview
Go deeper on lisocabtagene maraleucel + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisocabtagene maraleucel + ibrutinib.